Skip to main content
. Author manuscript; available in PMC: 2014 Jun 16.
Published in final edited form as: Clin Trials. 2013 Jan 18;10(2):280–291. doi: 10.1177/1740774512470315

Table 3.

Characteristics for risk-eligible and enrolled participants in the NSABP STAR trial

Minority White
Risk eligible,
n = 7749		 Percentagea Enrolled,
n = 1296		 Percentageb Risk eligible,
n = 83,576		 Percentagea Enrolled,
n = 18,451		 Percentageb
Number of first-degree relatives with breast cancer
  0 2310 29.8 412 17.8 29,885 35.8 5281 17.7
  1 3761 48.5 558 14.8 43,110 51.6 9766 22.7
  2 1373 17.7 256 18.6 9076 10.9 2877 31.7
  >3 305 3.9 70 23.0 1505 1.8 527 35.0
History of LCIS
  No 7374 95.2 1155 15.7 80,244 96.0 16,812 21.0
  Yes 375 4.8 141 37.6 3332 4.0 1639 49.2
History of breast atypical hyperplasia
  No 6669 86.1 932 14.0 73,848 88.4 14,358 19.4
  Yes 1080 13.9 364 33.7 9728 11.6 4093 42.1

LCIS: lobular carcinoma in situ; NSABP: National Surgical Adjuvant Breast and Bowel Project; STAR: Study of Tamoxifen and Raloxifene.

a

Percent of total risk-eligible women with the specified characteristic.

b

Percent of risk-eligible women with specified characteristic who enrolled.